1867-P: Lowering Diabetes Treatment Burden through a Switch to Insulin Patch Therapy

Introduction and Objective: Injection pain, needle aversion, having to carry supplies, and social stigma are common contributors to suboptimal dosing with MDI therapy. We investigated the impact of treatment with the CeQur Simplicity™ patch device on glycemic outcomes user perceptions compared with prior therapy. Methods: This was a single-arm, real-world, observational study. No changes in insulin dose or therapeutic management were performed by investigators during the 60-90 days of onboarding. The primary outcomes for this analysis were user perceptions of their glycemic status, changes in diabetes burden and adherence to treatment plan after using CeQur Simplicity for 60-90 days. Results: A total of 1,073 adults with diabetes were included in the analysis. Previous treatment methods varied (Pen 79.4%; VGO patch 4.6%; Syringe 4.6%; New to RAA 7.7%; Other 0.7%; Pump 0.9%; None 0.5%; and Unknown 1.7%. Within the full cohort, the two most common challenges reported were: “not wanting to take injections” (40.7%), and “missed injections” (32.1%). Among the 874 participants who provided their primary perceptions of the patch, a notable proportion stated or inferred improved diabetes management, improved engagement with prescribed bolusing, and reduced injections. (Figure 1) Conclusion: Insulin delivery with the CeQur Simplicity patch was associated with reduced treatment burden, improved diabetes management, and fewer reported challenges compared to previous therapy. Disclosure A. Carlson: Research Support; Current; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company. Other - Research support and consulting/speaking; Current; Insulet Corporation. Research Support; Current; Lexicon Pharmaceuticals, Inc. Advisory Panel; Current; MannKind Corporation. Other - Research support and advisory panel; Current; Medtronic, Novo Nordisk A/S, Zealand Pharma A/S. Advisory Panel; Current; Tandem Diabetes Care, Inc. J. Duffee: Employee; Current; CeQur SA. Employee; Ended; OrganOx. L. Morini: None. J. Allaire: None. C.G. Parkin: Consultant; Current; Abbott Diabetes, CeQur SA, Dexcom, Inc., Tandem Diabetes Care, Inc., MannKind Corporation, Roche Diagnostics. C. Carter: Employee; Current; CeQur SA.